Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION
**DOSAGE AND ADMINISTRATION** The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily. Days 3 through 7: Instill one drop up to four times daily while awake.
OPHTHALMIC
Medical Information
**INDICATIONS AND USAGE** ZYMAR® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: **Aerobic Gram-Positive Bacteria:**_Cornyebacterium propinquum\*__Streptococcus mitis\*__Staphylococcus aureus__Streptococcus pneumoniae__Staphylococcus epidermidis_ **Aerobic Gram-Negative Bacteria:**_Haemophilus influenzae_ \\* Efficacy for this organism was studied in fewer than 10 infections.
**CONTRAINDICATIONS** ZYMAR® solution is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication.
S01AX21
xs 01 ax 21
Manufacturer Information
ABBVIE PTE. LTD.
ALLERGAN SALES LLC
Active Ingredients
Documents
Package Inserts
Zymar Ophthalmic Solution PI.pdf
Approved: September 8, 2017